Raphael Pharmaceutical (RAPH) Assets Average (2021 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Assets Average came in at $30000.0 in Q2 2026, down 51.22% year-over-year from $61500.0 in Q2 2025, and little changed quarter-over-quarter from $30000.0 in Q4 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Assets Average (2021 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Assets Average across 6 years of filings, most recently posting $30000.0 for Q2 2026.
- In Q2 2026, Assets Average fell 51.22% year-over-year to $30000.0; the TTM figure through Jun 2026 stood at $30000.0 (down 51.22% YoY), while the FY2025 annual figure was $40000.0, down 69.92% from the prior year.
- Assets Average came in at $30000.0 for Q2 2026 at Raphael Pharmaceutical, roughly flat from $30000.0 in the prior quarter.
- In the past five years, Assets Average ranged from a high of $321000.0 in Q4 2023 to a low of $18500.0 in Q3 2025.
- Average Assets Average over 5 years is $158676.5, with a median of $158500.0 recorded in 2022.
- The largest YoY upside for Assets Average was 78.81% in 2024 against a maximum downside of 87.85% in 2024.
- Over 5 years, Assets Average stood at $227000.0 in 2022, then soared by 41.41% to $321000.0 in 2023, then sank by 87.85% to $39000.0 in 2024, then declined by 23.08% to $30000.0 in 2025, then changed by 0.0% to $30000.0 in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $30000.0 in Q2 2026, $30000.0 in Q4 2025, and $18500.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 30,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 18,500.00 |
| Jun 30, 2025 | 61,500.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Sep 30, 2024 | 89,500.00 |
| Jun 30, 2024 | 240,500.00 |
| Mar 31, 2024 | 296,000.00 |
| Dec 31, 2023 | 321,000.00 |
| Sep 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 134,500.00 |
| Mar 31, 2023 | 241,500.00 |
| Dec 31, 2022 | 227,000.00 |
| Sep 30, 2022 | 158,500.00 |
| Jun 30, 2022 | 188,000.00 |
| Mar 31, 2022 | 301,000.00 |
| Dec 31, 2021 | 242,000.00 |